Hemoglobinopathies Market Size By Indication Type, By
End-Users, By Test Type, By Geographic Scope And
Hemoglobinopathies Market Size And
Hemoglobinopathies Market was valued at USD 6.75 Billion in 2020 and is projected to
reach USD 14.86 Billion by 2028, growing at a CAGR of 10.37 % from 2021 to 2028.
Growth of the global hemoglobinopathy market is mainly driven by a growing
prevalence of hemoglobinopathies in developed nations, high disease occurrence in
underdeveloped nations, various supportive government initiatives, and non-
government organizational funding. The Global Hemoglobinopathies Market report
provides a holistic evaluation of the market. The report offers a comprehensive analysis
of key segments, trends, drivers, restraints, competitive landscape, and factors that are
playing a substantial role in the market.
Global Hemoglobinopathies Market Definition
Hemoglobinopathy is a genetic disorder that causes structural abnormalities in
hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are
inherited single-gene disorders of which sickle cell disease is the most common kind.
There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the
Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to
anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are
used as diagnostic tests to determine the presence of hemoglobinopathies. The disease
does not have a permanent cure; this has resulted in a growing demand for new product
innovations in the pharmaceutical sector.
Get | Download Sample Report @ https://www.verifiedmarketresearch.com/download-
Additionally, the high prevalence of the disease and the national control program are
driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals,
Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen
Idec are some of the key playe